

# Agenda

- 8:00 a.m. Registration and Breakfast**
- 8:45 a.m. Welcome and Opening**  
Hande Ozdinler, PhD, Associate Professor of Neurology, Northwestern University Feinberg School of Medicine  
Robert Kalb, MD, Director, Les Turner ALS Center, Chief of Neuromuscular Disease in the Department of Neurology, Professor of Neurology, Feinberg School of Medicine, Joan and Paul Rubschlager Professor  
Laura Freveletti, CEO of Les Turner ALS Foundation
- 9:00 a.m.-12:00 p.m. Research Presentations**
- 9:00-9:25 a.m. Untangling the convergence of disease mechanisms in ALS using personalized iPSC technologies** by Evangelos Kiskinis, PhD, Associate Professor of Neurology and Neuroscience, Northwestern University Feinberg School of Medicine
- 9:35-10:05 a.m. How neuronal stress and brain trauma may contribute to ALS pathogenesis** by Daryl Bosco, PhD, Professor and Associate Vice Chair, Professor of Neurology, UMass Chan Medical School
- 10:10-10:25 a.m. Potential role of cardiolipin nanoparticles in improving upper motor neuron health in amyotrophic lateral sclerosis** by Mukesh Gautam, PhD, Research Assistant Professor, Ellen McConnell Blakeman Fellow, Department of Neurology, Northwestern University Feinberg School of Medicine
- 10:30-10:45 a.m. Morning Break**
- 10:50-11:20 a.m. Countering deleterious phase transitions in ALS/FTD** by James Shorter, MA, PhD, Professor, Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania
- 11:25-11:55 a.m. From axon damage to disease: common mechanisms in neurodegeneration** by Claire Le Pichon, PhD, Investigator, National Institute of Child Health and Human Development
- 12:00-2:00 p.m. Lunch Break/Poster Session**
- 12:15 p.m. NU-9 Information Session (in-person only)**  
Hande Ozdinler, PhD, Associate Professor of Neurology, Northwestern University Feinberg School of Medicine
- 12:30 p.m. Poster Session Begins**
- 2:00 p.m. Opening Remarks for Afternoon Session**  
Laura Freveletti, CEO of Les Turner ALS Foundation
- 2:05 p.m. Keynote Address**  
Introduction: Robert Kalb, MD, Director of Les Turner ALS Center, Joan and Paul Rubschlager Professor  
**Antisense based therapy for rare neurological diseases by C. Frank Bennett, PhD, Executive Vice President, Chief Scientific Officer, Ionis Pharmaceuticals**  
Moderator: David Gate, PhD, Assistant Professor, Northwestern University Feinberg School of Medicine
- 3:20 p.m. Afternoon Break**
- 3:30 p.m. Les Turner ALS Foundation Video & Clinical Conversations Panel**  
Introduction: Erik Pioro, MD, PhD, Herbert C. Wenske Professor of Neurology, Vice-Chair of Translational Neurology, Medical Director, Neuromuscular Division  
Senda Ajroud-Driss, MD, Director, Lois Insolia ALS Clinic Les Turner ALS Center at Northwestern Medicine; Program Director, Neuromuscular Fellowship; Professor of Neurology  
Tina Cascio, RN, BSN, Board of Directors, Les Turner ALS Foundation  
Janie Gobeli, ALS Research Ambassador for the Northeast ALS Consortium
- 4:25 p.m. Closing Remarks**  
Robert Kalb, MD, Director of Les Turner ALS Center, Joan and Paul Rubschlager Professor